Iberdomide Clinical Trials
18 recruitingDrug
Phase 111Phase 210Phase 32
Showing 1–18 of 18 trials
Recruiting
Phase 2
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Multiple Myeloma
National Cancer Institute (NCI)78 enrolled74 locationsNCT06179888
Recruiting
Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 1
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche200 enrolled16 locationsNCT05583617
Recruiting
Phase 1
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie135 enrolled26 locationsNCT06896916
Recruiting
Phase 1Phase 2
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled40 locationsNCT06232044
Recruiting
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Multiple Myeloma
Canadian Myeloma Research Group75 enrolled7 locationsNCT05272826
Recruiting
Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb1,216 enrolled285 locationsNCT05827016
Recruiting
Phase 1
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Alfred Chung, MD32 enrolled1 locationNCT06348108
Recruiting
Phase 2
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Benjamin T Diamond, MD30 enrolled1 locationNCT05896228
Recruiting
Phase 1Phase 2
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Multiple Myeloma
Hackensack Meridian Health66 enrolled2 locationsNCT05199311
Recruiting
Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company147 enrolled19 locationsNCT06121843
Recruiting
Phase 3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
University of Heidelberg Medical Center411 enrolled69 locationsNCT06216158
Recruiting
Phase 1Phase 2
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Multiple MyelomaMyelomaRefractory Multiple Myeloma
Omar Nadeem, MD49 enrolled3 locationsNCT06518551
Recruiting
Phase 1Phase 2
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Recurrent Multiple Myeloma
Mayo Clinic37 enrolled1 locationNCT06785415
Recruiting
Phase 2
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Smouldering Myeloma
University College, London63 enrolled2 locationsNCT06762769
Recruiting
Phase 2
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Multiple Myeloma
Barbara Ann Karmanos Cancer Institute60 enrolled2 locationsNCT06107738